<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448253</url>
  </required_header>
  <id_info>
    <org_study_id>AX001</org_study_id>
    <nct_id>NCT00448253</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum</brief_title>
  <official_title>Safety and Pharmacokinetics of Anthrax Immune Globulin Intravenous (Human), NP-015, in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cangene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Cangene Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the pharmacokinetics of three doses of NP-015 (210, 420
      or 840 units TNA) in healthy volunteers. To evaluate the safety of NP-015 based on adverse
      events and laboratory assessments. To determine the dose proportionality relation of three
      different doses of NP-015.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The test product is Anthrax Immune Globulin Intravenous (Human), NP-015.

        -  The product is supplied as a sterile liquid suitable for IV administration.

        -  Product potency is expressed in units of anthrax toxin neutralization assays(TNA) per
           vial.

        -  This study is a phase 1, placebo controlled, dose-ranging study in healthy volunteers.
           Subjects will receive one of three NP-015 doses (210, 420 or 840 units TNA) or equal
           volumes of saline placebo.

        -  Enrolment will be sequential, starting at the lowest NP-015 dose with accrual into the
           next higher dose after all patients at the lower dose have been treated.

        -  The first 3 Cohorts: The Subjects will be recruited in cohorts of 24, with placebo
           controls included in each dosing group. In each cohort, subjects will be randomized to
           receive either NP-015 (N = 18/dosing group) or placebo (N = 6/dosing group). For Cohort
           4: 20 Subjects will be recruited and dosed at the highest dose with 2 additional product
           lots (10 subjects per lot).

      Plasma samples will be drawn over 84 days. Plasma will be tested for anti-anthrax antibodies
      by a protective antigen (anti-PA) ELISA and toxin neutralization assay (TNA).

        -  Serological testing for HIV, HBV and HCV will be conducted at screening to determine
           eligibility. Nucleic acid amplification testing (NAT) and serological testing for HIV,
           HBV and HCV will be conducted at baseline (day -1) and at the final visit (day 84 or
           early withdrawal). NAT for parvovirus B19 will be conducted at baseline (day -1), day
           14, and the final visit (day 84 or early withdrawal).

        -  Safety data will be collected throughout the 84-day study.

      Screening (within 28 days prior to Baseline):

        -  Informed consent

        -  Review of admission criteria

        -  Medical history, general physical examination, vital signs, electrocardiogram and
           concomitant medications will be recorded

        -  Hematology, blood chemistry, urinalysis, viral serology (anti-HIV-1/2, Anti-HCV, HBsAg,
           anti-HBc)

        -  Serum pregnancy test for all female subjects

        -  Drug screen (urine)

        -  Blood collection for anti-PA antibody and toxin neutralization assay (TNA) assessment

      Baseline (Day -1, within 24 hours prior to Day 0)

        -  Review of admission criteria

        -  Assessment of brief physical exam, vital signs, weight, hematology, blood chemistry,
           urinalysis, and concomitant medications

        -  Assessment of haptoglobin and free hemoglobin levels

        -  Update of medical history

        -  NAT testing for HIV, HBV, HCV and parvovirus B19, and serological testing for HIV, HBV
           and HCV

        -  Serum pregnancy test for all female subjects

        -  Alcohol (urine) and drug screen (urine)

        -  Blood collection for baseline anti-PA antibody and TNA assessment

        -  Subjects will be required to stay overnight following their baseline assessment

      NP-015 Administration (day 0)

        -  Following baseline assessment, NP-015 will be administered intravenously

        -  Urinalysis will be performed at the end of the infusion period (appearance and color,
           specific gravity, protein, glucose, pH, occult blood, ketones, microscopic examination)

      Assessments following the completion of NP-015 administration (1, 3 and 8 hrs; days 1, 3, 5,
      7, 9, 11, 14, 21, 28, 42, 56 and 84 or early withdrawal)

        -  Following NP-015 administration, blood will be collected for anti-PA antibody ELISA
           analysis and TNA assessment at each of the respective times.

        -  Assessment of vital signs, adverse events and concomitant medications.

      Additional Assessments:

        -  Days 1, 3, 7, 14, 28 and 84 or early withdrawal: Assessment of hematology, blood
           chemistry and urinalysis.

        -  Day 1: Assessment of haptoglobin and free hemoglobin levels.

        -  Day 14: NAT for parvovirus B19.

        -  Day 28: serum pregnancy test for female subjects.

        -  Final (day 84 or early withdrawal) visit: a general physical exam, serum pregnancy test
           for female subjects, and viral marker testing (NAT for HBV, HCV, HIV and parvovirus B19,
           and serology for HIV, HBV and HCV) will be performed.

      For Cohort 4 there will be no anti anthrax antibody testing and the subjects will be assessed
      for safety only, up to day 28.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-PA antibody and TNA for PK analyses.</measure>
    <time_frame>screen, baseline, and D0 hours 1,3,8 and day(s) 1,3,5,7,9,11,14,21,28,42,56 and 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Markers for safety.</measure>
    <time_frame>screen, baseline, and Day(s)14 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose proportionality analyses.</measure>
    <time_frame>screen, baseline, and D0 hours 1,3,8 and day(s) 1,3,5,7,9,11,14,21,28,42,56 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry</measure>
    <time_frame>screen, baseline, and D0 hours 0,1,2 and day(s) 1,3,7,14,28, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>screen, baseline, and D0 hours 0 and day(s) 1,3,7,14,28, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology (haptoglobin and free hemoglobin at baseline and day 1)</measure>
    <time_frame>screen, baseline, Day(s) 1,3,7,14,28, and 84</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Symptoms of Inhalational Anthrax</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA. And a Fourth Cohort at 840 units TNA with 2 additional product lots.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (equal volume to 210 U, 420 U, or 840 U TNA dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NP-015</intervention_name>
    <description>Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.
And a Fourth Cohort at 840 units TNA with 2 additional product lots.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
    <other_name>Anthrax Immune Globulin (AIG)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age 18/19 (dependent on local age of majority) - 55 years

          -  Body mass index of 19 - 29

          -  For female subjects that are not surgically sterilized, willingness to use an
             effective method of contraception throughout the trial including:

          -  Using hormonal contraception (oral, injectable or implant) continuously for 3 months
             prior to the start of the trial and willing to continue to use hormonal contraception
             throughout the entire trial.

          -  IUD inserted at least 3 months prior to dosing.

          -  For female subjects who are postmenopausal &lt; 2 years an FSH â‰¥ 40 mIU/mL must be
             obtained. If the FSH is &lt; 40 mIU/mL the subject must agree to use an acceptable form
             of contraception (see above).

          -  For males that have not had a vasectomy, willingness to use a condom with spermicide
             for the duration of the study. Also, male subjects must not donate sperm for the
             duration of the study.

          -  Normal and healthy as determined by medical history, physical exam, ECG, vital signs
             and laboratory tests of liver, kidney and hematological functions

          -  Written informed consent

        Exclusion Criteria:

          -  Heavy smokers (&gt;10 cigarettes/day) or individuals using smokeless tobacco or nicotine
             containing products

          -  Use of any investigational product within the past 30 days

          -  Recipient of any blood product within the past 12 months

          -  Plasma donation within 7 days or significant blood loss or blood donation within 56
             days of baseline

          -  Females with a hemoglobin level &lt; 12 g/dL

          -  Males with a hemoglobin level &lt; 13 g/dL

          -  History of hypersensitivity to blood products

          -  History of allergy to latex or rubber

          -  History of IgA deficiency

          -  Pregnancy or lactation

          -  Positive serology test for HIV or HCV, positive test for HBV as determined by HBsAg.

          -  History of, or suspected substance abuse problem (including alcohol)

          -  Failure of drug test at screening or baseline

          -  Failure of alcohol test at baseline or consumption of alcoholic beverages within 48
             hours of baseline

          -  History of anthrax vaccination with AVA or any other anthrax vaccine

          -  Individuals with planned medical procedures that will occur during the study

          -  Use of prescription medications within 7 days prior to baseline, or anticipated use
             during the study (with the exception of hormonal contraceptives for females)

          -  Use of over-the-counter, herbal medications or vitamins within 7 days of study
             admission

          -  An opinion of the investigator that it would be unwise to allow participation of the
             subject in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan S Marion, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2007</study_first_submitted>
  <study_first_submitted_qc>March 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2007</study_first_posted>
  <last_update_submitted>March 25, 2011</last_update_submitted>
  <last_update_submitted_qc>March 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Fran Yadao, Manager Clinical Operations</name_title>
    <organization>Cangene Corp.</organization>
  </responsible_party>
  <keyword>Inhalational Anthrax</keyword>
  <keyword>Human Immune globulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anthrax</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

